ESMO 2016

Nivolumab Improves Quality of Life versus Chemotherapy in Patients with Head and Neck Cancer

Phoebe Starr

November 2016, Vol 7, No 10 - ESMO 2016

Copenhagen, Denmark—In recent years, the personal experience of patients with cancer has been recognized as an important factor in determining the value of a treatment. According to patient-reported outcomes from the CheckMate-141 clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) Congress, patients’ quality of life (QOL) remained stable with the immunotherapy nivolumab (Opdivo), whereas it significantly deteriorated with chemotherapy. [ Read More ]

Angiogenesis Inhibitor Has Modest Effect on Progression-Free Survival in Metastatic Colorectal Cancer

Charles Bankhead

November 2016, Vol 7, No 10 - ESMO 2016

Copenhagen, Denmark—Patients with previously treated metastatic colorectal cancer (mCRC) had a small but significant improvement in progression-free survival (PFS) but no overall survival (OS) benefit after receiving the multikinase inhibitor nintedanib (Ofev), according to results from the LUME-Colon 1 clinical trial reported by principal investigator Eric Van Cutsem, MD, Clinical Digestive Oncology, University Hospitals Leuven, Belgium, at the 2016 European Society for Medical Oncology Congress. [ Read More ]

Adjuvant Ipilimumab Therapy Shows Long-Term Survival Benefit in Patients with High-Risk Melanoma

Charles Bankhead

November 2016, Vol 7, No 10 - ESMO 2016

Copenhagen, Denmark—Adjuvant immunotherapy with ipilimumab (Yervoy) led to significant improvement in long-term overall survival (OS) among patients with high-risk melanoma, according to results from a 5.3-year follow-up in a randomized clinical trial reported at the 2016 European Society for Medical Oncology Congress and published simultaneously online. [ Read More ]

Ribociclib-Letrozole Combination Potentially Practice-Changing in Advanced Breast Cancer

Phoebe Starr

November 2016, Vol 7, No 10 - ESMO 2016

Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%. [ Read More ]